160 related articles for article (PubMed ID: 37480496)
1. The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis.
Jin T; Wang W; Ge L; Li X; Ge M
Endocrine; 2023 Dec; 82(3):590-601. PubMed ID: 37480496
[TBL] [Abstract][Full Text] [Related]
2. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
3. Identification of iron metabolism-related genes as prognostic indicators for papillary thyroid carcinoma: a retrospective study.
Jin T; Ge L; Chen J; Wang W; Zhang L; Ge M
PeerJ; 2023; 11():e15592. PubMed ID: 37361050
[TBL] [Abstract][Full Text] [Related]
4. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
5. Siglec15 promotes the migration of thyroid carcinoma cells by enhancing the EGFR protein stability.
Huang S; Ji Z; Xu J; Yang Y; Wu B; Chen Q; Geng S; Si Y; Chen J; Wei Y; Wang C; Ai Z; Jiang J
Glycobiology; 2023 Jun; 33(6):464-475. PubMed ID: 37129515
[TBL] [Abstract][Full Text] [Related]
6. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
7. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
9. Unveiling the molecular features, relevant immune and clinical characteristics of
Hou X; Chen C; Lan X; He X
Front Immunol; 2022; 13():975787. PubMed ID: 36159823
[TBL] [Abstract][Full Text] [Related]
10. Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.
Hou X; Chen C; He X; Lan X
Dis Markers; 2022; 2022():1606404. PubMed ID: 35769818
[TBL] [Abstract][Full Text] [Related]
11. Multifocality Is not an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score-Matching Analysis.
Geron Y; Benbassat C; Shteinshneider M; Or K; Markus E; Hirsch D; Levy S; Ziv-Baran T; Muallem-Kalmovich L
Thyroid; 2019 Apr; 29(4):513-522. PubMed ID: 30799769
[TBL] [Abstract][Full Text] [Related]
12. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
[TBL] [Abstract][Full Text] [Related]
13. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
14. Correlations of ultrasound and pathological features of thyroid carcinoma with TC-1 mRNA and protein expression.
Zhang CL; Geng CH; Jian JJ; He M; Zhao HW; Li HY
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3440-3446. PubMed ID: 31081098
[TBL] [Abstract][Full Text] [Related]
15. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma.
Tunca F; Sormaz IC; Iscan Y; Senyurek YG; Terzioglu T
J Endocrinol Invest; 2015 Dec; 38(12):1327-34. PubMed ID: 26280320
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
17. Evaluate the diagnostic and prognostic value of NUSAP1 in papillary thyroid carcinoma and identify the relationship with genes, proteins, and immune factors.
Gao T; Zhao L; Zhang F; Cao C; Fan S; Shi X
World J Surg Oncol; 2022 Jun; 20(1):207. PubMed ID: 35710427
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-421 predicts poor prognosis and promotes proliferation, migration, and invasion of papillary thyroid cancer cells.
Dong A; Zhang J; Sun W; Hua H; Sun Y
J Chin Med Assoc; 2020 Nov; 83(11):991-996. PubMed ID: 32881717
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide scanning for CHD1L gene in papillary thyroid carcinoma complicated with type 2 diabetes mellitus.
Kang YY; Li JJ; Sun JX; Wei JX; Ding C; Shi CL; Wu G; Li K; Ma YF; Sun Y; Qiao H
Clin Transl Oncol; 2021 Dec; 23(12):2536-2547. PubMed ID: 34245428
[TBL] [Abstract][Full Text] [Related]
20. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
